Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma

We studied T-BiRD (thalidomide [Thalomid ® ], clarithromycin [Biaxin ® ], lenalidomide [Revlimid ® ] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1 – 28; lenalidomide 25 mg/day on days 1 – 21; and thalidomide 100 mg/day (50 mg/day on days 1 – 7 of cycle 1 only) on days 1 – 28. Twenty-six patients received a median of 6 cycles (range 0 – 41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of fi rst-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity aff ected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations. ClinicalTrials.gov identifi er: NCT00538733